Plans is the fifth album by Death Cab for Cutie. It was released on August 30, 2005. "Soul Meets Body" was the first single from the album, followed up by "Crooked Teeth" and "I Will Follow You Into The Dark". The album was nominated for a Grammy Award for 'Best Alternative Music Album' at the 48th Annual Grammy Awards, held February 8, 2006. The vinyl release of this album features the bonus track "Talking Like Turnstiles". The Japanese release includes the bonus track "Jealousy Rides With Me".
Plans has been certfied Gold in the US selling more than 500,000 copies.
Track listing
"'Marching Bands of Manhattan'" (Gibbard) – 4:12
"'Soul Meets Body'" (Gibbard) – 3:50
"'Summer Skin'" (Gibbard/McGerr/Walla) – 3:14
"'Different Names for the Same Thing'" (Gibbard) – 5:08
"'I Will Follow You Into the Dark'" (Gibbard) – 3:09
"'Your Heart is an Empty Room'" (Gibbard) – 3:39
"'Someday You Will Be Loved'" (Gibbard/Walla) – 3:11
"'Crooked Teeth'" (Gibbard/Walla) – 3:23
"'What Sarah Said'" (Gibbard/Harmer) – 6:20
"'Brothers on a Hotel Bed'" (Gibbard/Walla) – 4:31
[Mini-Review] Utility of Kallikrein-Related Peptidases (KLKs) as Cancer Biomarkers Emami, N., Diamandis, E. P. Mon, 29 Sep 2008 00:00:00 -0000
Background: The human kallikrein-related peptidase (KLK) family consists of 15 highly conserved serine proteases, which are encoded by the largest uninterrupted cluster of protease genes in the human genome. To date, several members of the family have been reported as potential cancer biomarkers. Although primarily known for their biomarker value in prostate, ovarian, and breast cancers, more recent data suggest analogous roles of KLKs in several other cancers, including gastrointestinal, head and neck, lung, and brain malignancies. Among the proposed KLK cancer biomarkers, prostate-specific antigen (also known as KLK3) is the most widely recognized member in urologic oncology.
Content: Despite substantial progress in the understanding of the biomarker utility of individual KLKs, the current challenge lies in devising biomarker panels to increase the accuracy of prognosis, prediction of therapy, and diagnosis. To date, multiparametric KLK panels have been proposed for prostate, ovarian, and lung cancers. In addition to their biomarker utility, emerging evidence has revealed a number of critical functional roles for KLKs in the pathogenesis of cancer and their potential use as therapeutic targets.
Summary: KLKs have biomarker utility in many cancer types but individually lack sufficient specificity or sensitivity to be used in clinical practice; however, groups of KLKs and other candidate biomarkers may offer improved performance.
[Mini-Review] High-Abundance Polypeptides of the Human Plasma Proteome Comprising the Top 4 Logs of Polypeptide Abundance Hortin, G. L., Sviridov, D., Anderson, N. L. Mon, 29 Sep 2008 00:00:00 -0000
Background: Plasma contains thousands of proteins, but a small number of these proteins comprise the majority of protein molecules and mass.
Content: We surveyed proteomic studies to identify candidates for high-abundance polypeptide chains. We searched the literature for information on the plasma concentrations of the most abundant components in healthy adults and for the molecular mass of the mature polypeptide chains in plasma. Because proteomic studies usually dissociate proteins into polypeptide chains or detect short peptide segments of proteins, we summarized data on individual peptide chains for proteins containing multiple subunits or polypeptides. We collected data on about 150 of the most abundant polypeptides in plasma. The abundant polypeptides span approximately the top 4 logs of concentration in plasma, from 650 to 0.06 µmol/L on a molar basis or from about 50 000 to 1 mg/L mass abundance.
Conclusions: Data on the concentrations of the high-abundance peptide chains in plasma assist in understanding the composition of plasma and potential approaches for clinical laboratory or proteomic analysis of plasma proteins. Development of more extensive databases regarding the plasma concentrations of proteins in health and diseases would promote diagnostic and proteomic advances.